AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03709524 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq
Description: video laryngoscope with a monitor
Study NCT03092180 — intervention group
Intervention type: DRUG
Intervention: Intravenous Infusion
Description: Intravenous infusion of follow medicine at disease onset: methyprednisolone and/or human intravenous immunoglobulin
Study NCT03709524 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasotracheal Airtraq + styletted tube
Description: video laryngoscope with a monitor
Study NCT02158702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide and Dexamethasone
Description: Pomalidomide will be given at 4mg once daily for 21 days in a 28-day cycle. Dexamethasone will be given at a dose of 40mg orally once a week for 4 weeks (D1,8,15,22).
Study NCT01830296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil+morphine
Description: Morphine, Remifentanil+Morphine
Study NCT03543358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rovalpituzumab tesirine
Description: Optional retreatment with rovalpituzumab tesirine (0.3 mg/kg or previously adjusted dose) administered intravenously once every 6 weeks beginning on Day 1 (day of dosing) for 2 dose cycles
Study NCT03543358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rovalpituzumab tesirine
Description: Rovalpituzumab tesirine (0.3 mg/kg or previously adjusted dose) administered intravenously once every 6 weeks beginning on Day 1 (day of dosing). Subjects will receive rovalpituzumab tesirine on Day 1 of each 6-week cycle, omitting every third cycle until disease progression or study drug discontinuation.
Study NCT00698061 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine 208129
Description: 3-dose primary vaccination and booster vaccination by intramuscular injection
Study NCT00698061 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: 3-dose primary vaccination and booster vaccination by intramuscular injection
Study NCT03519516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-174
Description: Pharmaceutical form: ophthalmic solution~* Prepared by: Laboratorios Sophia, S.A. of C.V.~* Description of the solution: transparent solution, free of visible particles.~* Description of container: sterile multi-dose bottle
Study NCT03519516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sophixín Ofteno®
Description: * Active substance: Ciprofloxacin 0.3%~* Pharmaceutical form: Ophthalmic solution~* Prepared by: Laboratorios Sophia, S.A. of C.V.~* Description of the solution: transparent solution, free of visible particles.~* Description of container: sterile multi-dose bottle
Study NCT04427436 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study NCT01884168 — intervention group
Intervention type: BIOLOGICAL
Intervention: Dc-CIK immunotherapy
Description: The patients with malignant cavity effusion are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) locally.
Study NCT02518308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: The Mindfulness-Based Stress Reduction program involves instruction in mindfulness meditation and yoga.
Study NCT02387372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/Tazobactam - Multiple Doses
Description: 4-6 doses of ceftolozane/tazobactam every 8 hours as a 60-minute intravenous infusion as follows:~* Participants with CLCR > 50 mL/min will receive 4-6 doses of 3 g ceftolozane/tazobactam every 8 hours~* Participants with CLCR 30 - 50 mL/min will receive 4-6 doses of 1.5 g ceftolozane/tazobactam every 8 hours~* Participants with CLCR 15 - 29 mL/min will receive 6 doses of 750 mg ceftolozane/tazobactam every 8 hours
Study NCT02387372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/Tazobactam - Single Dose
Description: Single dose of ceftolozane/tazobactam, 3 g, as a 60-minute intravenous infusion
Study NCT01925859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EryDex (dexamethasone sodium phosphate encapsulated erythrocytes)
Description: erythrocytes encapsulated with dexamethasone sodium phosphate (EryDex System)-corresponding to either 50 mg OR 125mg of experimental study drug
Study NCT01522040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Continuous magnesium drip, titrated to effect until patient's symptoms improve
Study NCT01522040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Simple saline drip, without active drug
Study NCT03894774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive in-patient psychotherapy treatment
Description: Intensive non-pharmaceutical in-patient intervention with high degrees of individual psychotherapy (5 sessions a week, psychodynamic and specific trauma therapy), group therapy (music-, arts-, sports- and concentrative movement therapy - each one session a week) as well as an ongoing milieutherapeutic setting where patients live during the whole treatment (approximately a 1:1-Ratio caregiver per patient is given) of 6 to 8 month treatment duration.
Study NCT02600052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF
Description: RESPIRATORY PATTERN PROPRIOCEPTIVE NEUROMUSCULAR FACILITATION
Study NCT03894774 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Combination of behavioral or psychoanalytic outpatient psychotherapy and pharmacotherapy
Study NCT03311399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SSI Screening Tool used in home visits by CHWs
Description: Individuals in Arm 1 will be visited at home by the sCHW who will administer the optimized SSI protocol via the mHealth device. Following the screening, the sCHWs will use the cell phone to photograph the surgical wound and record the GPS location of the visit.
Study NCT02600052 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: treadmill
Description: AEROBIC TRAINING
Study NCT02600052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: treadmill
Description: AEROBIC TRAINING
Study NCT03511651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP
Description: Two PEEP levels will be used during mechanical ventilation.
Study NCT03511651 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: PEEP
Description: Two PEEP levels will be used during mechanical ventilation.
Study NCT03311399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SSI Screening Tool used via phone call follow-up
Description: Individuals in Arm 2 will be phoned by the sCHW who will administer the SSI protocol over the phone.
Study NCT01026389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotarem
Description: DOTAREM, 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus
Study NCT01026389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadovist
Description: Gadovist, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus
Study NCT04094766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy
Description: Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy by intravenous injection.
Study NCT03503214 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: In vitro determination of non-carbonic buffer power
Description: In vitro measurement of the non-carbonic buffer power by the means of equilibration of whole blood and isolated plasma with gas mixtures containing different concentrations of carbon dioxide
Study NCT03883529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Writing about and reviewing birth experience
Description: Writing about and reviewing birth experience with a known midwife from antenatal care about 6 weeks post-partum.
Study NCT00875160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT2101
Description: 225mg (nine 25mg capsules total dose) to be taken by mouth every day for 9 days (Study Days 1, 3-10)
Study NCT04450199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D2
Description: Vitamin D tablets
Study NCT04450199 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Over encapsulated sugar pills
Study NCT01013246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1-hour video game play
Description: FIFA 2009, a football video game played on Xbox 360
Study NCT01599117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company. Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
Study NCT01599117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Udenafil (Zydena)
Description: Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
Study NCT00761709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-39256 Ophthalmic Suspension, 1%
Study NCT00761709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost Ophthalmic Solution, 0.005%
Study NCT00761709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Inactive ingredients used as a placebo comparator
Study NCT00761709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle
Description: Inactive ingredients used as a placebo comparator
Study NCT03222323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine perineurally
Description: Dexmedetomidine is added perineurally on one side and will influence the nerve block perineurally on this side. Dexmedetomidine is also absorbed and redistributed systemically and will influence the opposite ulnar nerve block systemically.
Study NCT03222323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 5mg/ml
Description: Ropivacaine is used in 5mg/ml in the perineural, systemic and placebo nerve blocks.
Study NCT03222323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine 5mg/ml
Description: Ropivacaine is used in 5mg/ml in the perineural, systemic and placebo nerve blocks.
Study NCT03222323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 5mg/ml
Description: Ropivacaine is used in 5mg/ml in the perineural, systemic and placebo nerve blocks.
Study NCT03222323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 7.5mg/ml
Description: In the high dose ropivacaine group a ropivacaine concentration of 7.5mg/ml is used.
Study NCT03448042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Runimotamab
Description: Runimotamab will be administered via IV infusion until disease progression, intolerable toxicity, or any other discontinuation criteria are met.
Study NCT03448042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered via IV infusion
Study NCT03222323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine systemically
Description: Dexmedetomidine administered perineurally on one side is absorbed and redistributed systemically and will influence the opposite ulnar nerve block systemically.
Study NCT03503214 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Classic description of acid-base status
Description: Measurement of plasma electrolytes, hemoglobin concentration, albumin and phosphates to compute acid-base variables according to Stewart's approach.
Study NCT03222323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline
Description: placebo (saline) is administered perineurally in all but the perineural group.
Study NCT03222323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: placebo (saline) is administered perineurally in all but the perineural group.
Study NCT03448042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab if needed
Study NCT01432574 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil
Description: The First Shot: Given on the day participants joined the study (Visit 1). The Second Shot: Given about 2 months later (Visit 2). The Third Shot: Given about 6 months after the first (Visit 3).
Study NCT01120652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Skills Training (MBST)
Description: This is a behavioral intervention that blends cognitive-behavioral therapy methods, mind-body relaxation training, and mindfulness practices. MBST is provided in 8 individual sessions, each lasting approximately one hour. Ideally, sessions take place on a weekly basis, so that the intervention phase of the study lasts for approximately two months.
Study NCT02831712 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Ferrous Fumarate
Description: One tablet of a commercial iron supplement (Ferrous Fumarate 200 mg, from Drug House of Australia) will be provided to participants after overnight fast. The intervention is only one time.
Study NCT04624178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib at 600 mg, orally, twice daily, continuously for 28 days.
Study NCT04624178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480mg intravenously on day 1 of every four-week cycle.
Study NCT03096886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-Augmented Cognitive Behavioral Therapy
Description: The model of CCBT, Good Days Ahead (GDA) will be utilized, it has been found that it is not inferior to CBT in MDD treatment efficacy. CCBT participants will complete 9 modules of the GDA program, including 240 minutes of computer training; participants will also meet with a therapist on 6 occasions for a total of 180 minutes of clinician administered cognitive behavioral therapy.
Study NCT02709928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-0714
Study NCT02709928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04574921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light Therapy System (LTS): Active setting
Description: Exposure for 1 hour á day for consecutive days.
Study NCT04574921 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Light Therapy System (LTS): Sham setting
Description: Exposure for 1 hour á day for consecutive days.
Study NCT00321269 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single Illness Management
Description: 8 week nursing intervention addressing Congestive Heart Failure
Study NCT00321269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comorbid Illness Management
Description: 8 week nursing intervention to address Congestive Heart Failure and emotional coping
Study NCT03126331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab monotherapy will be administered dosed at 480mg IV over 30 minutes for all patients every 4 weeks, regardless of weight (when given in combination with ipilimumab, the dose of nivolumab is 3mg/kg every 3 weeks).~Tumor assessed after 12 weeks If tumor decreases by 10% or more, then hold drug for 12 week and test tumor again. Continue treatment if tumor is not decreased by 10% or more.
Study NCT03126331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is dosed at 1mg/kg over 30 minutes every 3 weeks
Study NCT04000087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-enabled ECG-based Screening Tool
Description: A novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis and management of left ventricular systolic dysfunction.
Study NCT04498819 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wearable Activity Trackers, Exercise Prescription and Virtual Care
Description: The intervention is merging wearable activity trackers and tailored aerobic exercise prescriptions into the PCDSP's virtual STAND (a biweekly, evidence based, lifestyle medicine) program.~Participants will wear activity trackers for a week to collect baseline step data (used to create tailored step prescriptions). Biweekly, new step prescriptions will be tailored to each participant based on the previous two week's step count data. The intervention will add onto STAND classes by using activity tracker data into the class discussion for learning opportunities, as well as goal setting and action planning. The day of class, participants will receive a summary email new prescription and encouragement to continue to work hard, using the previous weeks' data to reinforce motivation. The activity tracker will provide instant feedback about step goals, sedentary behaviour and exercise minutes. Individual calls every other week will ensure adherence to exercise regime.
Study NCT00178464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: 81 mg flavored chewable tablets. Subjects between the ages of 2.0 and 4.99 years will receive half of an 81 mg aspirin tablet each day. Those older than 5.0 years will receive a daily 81 mg aspirin tablet. The subject will receive the study drug for a period of 12 months.
Study NCT01213069 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: The subjects are asked to fill out a questionnaire on the personal and professional situations, organ donation legislation, what happens in everyday practice, their own experience with donating their own organs, and what position they take.
Study NCT04119817 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mucosave® capsules
Description: 400 mg/day of Mucosave® capsules for a period of 8 weeks, once a day.
Study NCT04119817 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400 mg/day of placebo capsules for a period of 8 weeks, once a day.
Study NCT04247815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-450
Description: Oral, small molecule MK2 inhibitor
Study NCT04247815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo tablet manufactured to match ATI-450 in appearance
Study NCT04247815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 7.5 mg to 25 mg weekly
Study NCT04247815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: 7.5 mg to 25 mg weekly
Study NCT02910544 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Intensive dietary intervention
Description: Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
Study NCT02767453 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound drainage
Description: Experimental portion removing/draining blood/fluid from a space created during a surgical procedure. Typically, surgeons place a plastic tube in the shoulder joint to drain fluids that may accumulate after surgery. Hemovac drain is a FDA-approved device routinely used or wound drainage; however, there is no known evidence whether this improves outcomes of surgery.
Study NCT02767453 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Shoulder Arthroplasty
Description: Standard procedure for treating the severe pain and stiffness that often result at the end stage of various forms of arthritis or degenerative joint disease of the shoulder joint. The primary goal of shoulder replacement surgery is pain relief, with a secondary benefit of restoring motion, strength, function, and assisting with returning patients to an activity level as near to normal as possible. Shoulder prosthesis is a standard artificial device to replace both components of the ball and socket joint during TSA.
Study NCT01697267 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab IV infusion 1000 mg x 1 dose at months 4, 8, 12, 16 and 20 and glucocorticoids. Four - six hour infusion. Treatment with rituximab will cease at month 20.
Study NCT01697267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Oral dosage form. Target dose is 2mg/kg; maximum daily dose is 200mg. This should be continued until month 24. The dose should then by reduced by 50% and azathioprine completely withdrawn at month 27.~The dose should be rounded down to the nearest 25mg. The dose may vary on alternate days e.g. 100mg one day, 150mg the next for patients on an overall dose of 125mg daily.~If patients are aged over 60 years, reduce the dose by 25%. If patients are aged over 75 years, reduce the dose by 50%.
Study NCT01240655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCL161
Study NCT01240655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel